The Continental landscape is witnessing a fascinating evolution in the understanding of psychedelics. Historically stigmatized, these substances have begun to receive attention for their potential therapeutic applications. From Germany, where clinical trials are in progress, to the UK, where open conversations is expanding, Europe stands out in thi